Biotech Archives - Page 15 of 733

1 minute read

Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024

June 3, 12:02 PM

First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1

CRNX

2 minute read

Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients

By Vandana Singh

June 3, 12:01 PM

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile.

JNJ

2 minute read

Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate

By Vandana Singh

June 3, 11:11 AM

Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study.

GPCR

2 minute read

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

By Vandana Singh

June 3, 10:27 AM

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.

MRK

2 minute read

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward

By Vandana Singh

June 3, 9:53 AM

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.

GSK

1 minute read

Precigen Announces Study Data For PRGN-2012 For Recurrent Respiratory Papillomatosis Patients; Phase 1/2 Pivotal Study Met Primary And Efficacy Endpoints

By Benzinga Newsdesk

June 3, 9:31 AM

– Phase 1/2 pivotal study met the primary safety and efficacy endpoints –– 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012;

PGEN

1 minute read

Kite, A Gilead Company Presents New Data On Yescarta For Relapsed/Refractory Central Nervous System Lymphoma

By Benzinga Newsdesk

June 3, 9:11 AM

-- At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed ---- Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of

GILD

1 minute read

Evaxion Presents Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed EVX-01 Vaccine At The ASCO Annual Meeting 2024

By Benzinga Newsdesk

June 3, 8:47 AM

Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of

EVAX

1 minute read

Enlivex Receives Regulatory Authorization For The Initiation Of A Placebo-Controlled Phase I/II Trial Evaluating Allocetra In Up To 46 Patients With Thumb Osteoarthritis

By Benzinga Newsdesk

June 3, 8:43 AM

First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy Third study of AllocetraTM in osteoarthritis, following

ENLV

1 minute read

Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential As A Precision Medicine For Cancer

By Benzinga Newsdesk

June 3, 8:38 AM

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE

CYCC